Predicting pediatric inflammatory bowel disease remission utilizing a clinical decision support tool

Area of Science:

• Pediatric Gastroenterology
• Inflammatory Bowel Disease (IBD) Research
• Clinical Decision Support Systems

Background:

• The American Gastroenterological Association's CDST predicts IBD remission in adults based on advanced therapy.
• Predictors of treatment response in pediatric IBD may differ from adults.
• Non-anti-tumor necrosis factor (TNF) biologics are increasingly used in pediatric IBD.

Purpose of the Study:

• To evaluate the predictive ability of the CDST for remission in pediatric IBD patients.
• To assess CDST performance in children treated with vedolizumab (VDZ) or ustekinumab (UST).
• To determine if CDST applicability extends to non-anti-TNF biologic therapies in pediatric IBD.

Main Methods:

• Retrospective review of 170 pediatric IBD patients (2-21 years) treated with VDZ or UST.
• Analysis of baseline characteristics to generate CDST scores.
• Comparison of CDST scores with week 52 steroid-free clinical remission (SFR) outcomes, stratified by disease type and prior anti-TNF exposure.

Main Results:

• 64% of patients achieved SFR at week 52.
• CDST score significantly predicted SFR in the overall cohort, ulcerative colitis (UC), and Crohn's disease (CD) groups (p<0.001).
• A CDST score >19 demonstrated high sensitivity for predicting SFR, particularly in patients previously treated with anti-TNF therapies and those on VDZ.

Conclusions:

• The CDST shows applicability in predicting week 52 SFR in pediatric UC and CD patients.
• A CDST score exceeding 19 is a highly sensitive indicator for predicting SFR in this pediatric IBD population.
• The tool's predictive value is notable in anti-TNF exposed patients and those receiving VDZ.